Jan
11
2022
On demand

Cell and gene therapy matures: Streamlining and smoothing the path to commercialization

The cell and gene therapy (CGT) industry is coming of age with multiple approved products in both AAV and gene-modified cell therapy. As the field continues to grow and mature, the advantages of integrated products and solutions for therapeutic developers is becoming apparent. Typically CGT program development requires managing multiple relationships and this presents challenges in aligning timelines. In this talk learn how Charles River's portfolio of products and services helps to enable our partners to streamline their path to commercialization.

  • Snapshot of Charles River’s CGT development portfolio
  • An in-depth look at early activities including antibody generation and target screening (basal activity, on-target/off-target binding)
  • Cell supply considerations for autologous and allogeneic programs
  • Plasmid, vector, and cell therapy manufacturing overview

Matt Hewitt, PhD

Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories

Matthew Hewitt, PhD, currently serves as Senior Director, Scientific Services, Cell and Gene Therapy (CGT) at Charles River Laboratories. Matt plays a critical role in driving CGT strategic vision as well as leading one of Charles River’s CGT sites.

Before joining the company, he was Head of R&D and Clinical Development for Lonza’s Personalized Medicine Business Unit where he led development of the Cocoon manufacturing technology, a closed, automated, scalable cell therapy manufacturing solution. In addition, he developed and executed numerous collaborations across academia and industry that leveraged the Cocoon technology. 

Prior to Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals, which focused on improving cell therapy efficacy in solid tumors. He also led the Immunology group at the University of Pennsylvania’s Gene Therapy Program, leading and contributing to numerous AAV gene therapy programs.

Matt received his PhD in Biophysics and Physiology from the University of Alabama at Birmingham and completed his postdoctoral fellowship at Johns Hopkins University.

SPEAKERS

Matt Hewitt, PhD
Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories

You might also like

Simplifying analytical development for viral vector production: robust...

S Kashi Ranganath
Srinath Kashi Ranganath
Srinath Kashi Ranganath
Staff Scientist, Field Applications, Pharma Analytics Group at Thermo Fisher Scientific
3 Mar 2022
38
Days
17
Hrs
28
Min
Register

Introducing Lonza’s AAV suspension transient transfection platform to...

S Sanyal
Suparna Sanyal
Suparna Sanyal
Head of Viral Vectors Commercial Development at Lonza Pharma & Biotech
24 Feb 2022
31
Days
17
Hrs
28
Min
Register

AAV manufacturing process development using fast USP and DSP HPLC analytics

A Štrancar
Aleš  Štrancar
Aleš Štrancar
Chief Executive Officer at BIA Separations
17 Feb 2022
24
Days
17
Hrs
28
Min
Register

How to monitor protein impurities to ensure consistent cell and gene...

E Mørtz
Ejvind Mørtz
Ejvind Mørtz
Co-Founder & COO at Alphalyse
15 Feb 2022
22
Days
17
Hrs
28
Min
Register

TESSA technology: A new era for AAV manufacture

R Cawood
Ryan Cawood
Ryan Cawood
Chief Scientific Officer at OXGENE
10 Feb 2022
17
Days
17
Hrs
28
Min
Register